MYD88 and diffuse large B-cell lymphoma: Thus, the identification of SPIBhigh/BATFlow mRNA expression may provide a tool to identify a subset of ABC-DLBCL patients with MYD88-L265P mutation who have a good response to current immunochemotherapy.